Logo Image
|Videos|October 1, 2017

Hospital Epidemiologists Should Continually Tailor Bundles to Ensure Effectiveness

Silvia Munoz-Price, MD, PhD, explains why infection control bundles should evolve as the problems faced by hospital epidemiologists continue to change.

Silvia Munoz-Price, MD, PhD, associate professor of clinical medicine at the Institute for Health and Society, Medical College of Wisconsin, and enterprise epidemiologist for Froedtert & the Medical College of Wisconsin, explains why infection control bundles should evolve as the problems faced by hospital epidemiologists continue to change. Dr. Munoz-Price stresses that hospital epidemiologists should tailor the bundles so that they can remain relevant and effective.

Related to this article

View more
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Read more
The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Read more
ID Week Highlights Part 1
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Read more